PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth’s ConfirmMDx™ for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies - Multi-Center MATLOC data presented at AUA Annual Meeting -
MDxHealth’s ConfirmMDx™ for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies


NewswireToday - /newswire/ - Liege, Belgium, 2012/05/23 - Multi-Center MATLOC data presented at AUA Annual Meeting - NYSE Euronext: MDXH

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx™ for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

In men suspected to have prostate cancer, the potential for false-negative biopsy results is well documented in the literature. Approximately twenty-five percent of men receiving a negative histopathology result, the gold standard for diagnosis, could be harboring occult cancer. Fear over this issue leads to additional physician visits, screening, and repeat biopsies, often on prostate-cancer-free men. MDxHealth’s ConfirmMDx test assesses the DNA methylation status of genes associated with prostate cancer. The test will help urologists differentiate patients with a true-negative biopsy from those who may have cancer undetected by prostate biopsy and histopathological review.

The data from the MATLOC (Methylation Analysis To Locate Occult Cancer) study presented during the Late Breaking Science Forum yesterday at the American Urology Association (AUA) Annual meeting in Atlanta, USA, revealed that the ConfirmMDx for Prostate Cancer test is a powerful tool to aid urologists in addressing false-negative biopsy concerns.

"With a high negative predictive value, exceeding that of standard microscopic histopathology review, the MATLOC study results demonstrate that the ConfirmMDx for Prostate Cancer test can help urologists confirm true-negative biopsy results, providing peace-of-mind and reducing unnecessary repeat biopsies,” explained principle investigator Dr. Grant Stewart from the Edinburgh Urological Cancer Group at the University of Edinburgh, who presented the data. “The test will also help urologists identify high-risk men who may have occult cancer, enabling more effective triage of these patients with a repeat biopsy and treatment as required."

"These data confirm the high negative predictive value (NPV) and clinical utility of the ConfirmMDx for Prostate Cancer genes and DNA methylation technology previously reported in published studies. We believe the test fulfills an unmet medical need, complementing the current standard of care, and holds the potential to reduce unnecessary invasive procedures and the associated healthcare expenditures. Prostate biopsies pose significant risk of trauma and infection, at times requiring hospitalization. As a consequence, approximately one-third of men refuse to endure a repeat biopsy despite fear of a false- negative result, leaving these men at risk for disease progression. ConfirmMDx, a non- invasive assay performed on the residual prostate tissues from the previous negative biopsy, provides critical insights beyond histopathology to enable more informed patient management decisions," said Dr. Jan Groen, CEO of MDxHealth. "We are pleased to announce that ConfirmMDx for Prostate Cancer is now available to urologists directly through MDxHealth’s state-of-the-art CLIA laboratory, and via our co-marketing partner PLUS Diagnostics.”

Study Details
The multicenter MATLOC study involved 3 sites from the UK and Belgium, testing tissue from initial negative biopsies and comparing assay results to cancer detection in subsequent biopsies within 30 months revealing either cancer (cases) or negative results (controls). Individual prostate biopsies comprised 10 separate tissue cores on average. ConfirmMDx for Prostate Cancer was used to analyze the methylation status of a panel of validated biomarkers (GSTP1, APC and RASSF1) in 4,681 archived prostate biopsy cores from 483 men in a blinded fashion. Results demonstrated that the assay had a NPV of 90%

Application of this assay to initial, negative prostate biopsies accurately identified over two- thirds of patients who had cancer detected on a subsequent prostate biopsy, while correctly confirming negative findings in approximately two-thirds of men who were cancer-free in a subsequent prostate biopsy. The high NPV of 90% indicates this assay could help avoid unnecessary repeat prostate biopsies.

Approximately 60% of positive assay results were indicated by one methylated gene while the remaining 40% of cases displayed two or more methylated genes. Univariate analyses identified that the methylation panel was a significant predictor of prostate cancer diagnosis. These findings were confirmed with a multivariate logistic regression, correcting for PSA, age, digital rectal examination results prior to initial biopsy and histopathological findings of this biopsy.

The study entitled “Clinical utility of a multiplexed epigenetic gene assay to detect cancer in histopathologically negative prostate biopsies: results of the multicenter MATLOC study”, was presented by Dr. Grant Stewart from the Edinburgh Urological Cancer Group at the University of Edinburgh, on Tuesday, May 22, 2012 during the late breaking science session. Abstracts from the conference are available online.

Over 650,000 American men receive a negative prostate biopsy result each year; however approximately 25-35% of these results are false negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on prostate-cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular “halo” around a cancer lesion can be present despite having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying men who may forego unnecessary repeat biopsies.

About MDxHealth
MDxHealth ( is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. Follow us on Twitter at:
Dr. Jan Groen will present on MDxHealth on June 19th at 9:30 at the 2012 BioInternational Convention that is taking place in Boston (June 18-21)

For more information:

Mike Sinclair, Halsin Partners
T: +44 20 7318 2955 / C: +44 7968 022075
E: msinclair[.]

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: MDxHealth, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

MDxHealth’s ConfirmMDx™ for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

MDxHealth, Inc. |
Publisher Contact: Dr. Jan Groen - 
949-812-6979 / +32 4 364 20 70 info[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From MDxHealth, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (